GLP-2 Overview:
A novel, dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist used for the treatment of type 2 diabetes and obesity.
------
Molecular Composition
A synthetic peptide composed of 39 amino acids. It has a modified structure that allows it to act on both the GLP-1 and GIP receptors. The peptide sequence is engineered to resist degradation by dipeptidyl peptidase-4 (DPP-4), which prolongs its half-life and enhances its clinical effect. The compound is conjugated to a fatty acid moiety, which increases its binding to albumin, thereby extending its duration of action.
------
Molecular Formula:
C₂₂₅H₃₄₁N₄₉O₆₈
Molecular Weight: 
Approximately 4813 Da
-----
Mechanism of Action
Acts as a dual agonist at both the GIP and GLP-1 receptors, enhancing glucose metabolism and promoting weight loss through complementary pathways:
------
1. GLP-1 Receptor Agonism
GLP-1 (Glucagon-Like Peptide-1) is an incretin hormone produced by intestinal L-cells in response to food intake.
----
Binds to and activates the GLP-1 receptor, leading to increased insulin secretion from pancreatic beta cells (in a glucose-dependent manner).
-----
Decreased glucagon secretion from pancreatic alpha cells (reducing hepatic glucose production).
----
Slowing of gastric emptying, leading to increased satiety and reduced appetite.
----
Reduced food intake through central effects on appetite regulation (acting on the hypothalamus).
------
2. GIP Receptor Agonism
GIP (Glucose-Dependent Insulinotropic Polypeptide) is an incretin hormone secreted by K-cells of the small intestine in response to nutrient intake.
Activation of the GIP receptor results in enhanced insulin secretion in response to glucose.
----
Improved insulin sensitivity in peripheral tissues (such as muscle and fat).
Synergistic effects with GLP-1 on appetite suppression and weight loss.
-----
3. Combined GLP-1 and GIP Effects
The dual agonism of GLP-1 and GIP receptors results in greater glycemic control and weight reduction compared to GLP-1 receptor agonism alone. GIP receptor activation may counteract the gastrointestinal side effects often associated with GLP-1 receptor activation, enhancing tolerability.
-------
This peptide is for research purposes ONLY. It is not approved for human consumption or medical use. All handling and usage must comply with applicable regulations and guidelines for laboratory research. By purchasing this product you agree to the condition of its handling by qualified laboratory professionals only. 
----------
Additional information:
*The product (substance) isn't a food or diet supplement.
*Keep out of children's reach
*Keep container tightly closed.
*Store below 8°C; protect from moisture.
*Store only in the original container.
*Avoid contact during pregnancy and breast feeding.
*Consult a doctor in the event of feeling unwell or having adverse effects related to the contact with the substance.